Schedule 13G ownership disclosure

Syndax Pharmaceuticals Inc

Common Stock · CUSIP: 87164F105

Event date: 2025-12-31

Filing-level shares
6,230,334
Percent of class
7.16%
  • The Vanguard Group

    Shares: 6,230,334 · Class: 7.16%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000102909-26-000252
Form type
SCHEDULE 13G/A
Filer
Syndax Pharmaceuticals Inc
CIK
CIK 1395937
Filed
Jan 30, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub